These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1518 related articles for article (PubMed ID: 28878676)

  • 1. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
    Alsaab HO; Sau S; Alzhrani R; Tatiparti K; Bhise K; Kashaw SK; Iyer AK
    Front Pharmacol; 2017; 8():561. PubMed ID: 28878676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
    Kok VC
    Front Oncol; 2020; 10():268. PubMed ID: 32185135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer.
    Alkholifi FK; Alsaffar RM
    Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
    Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
    Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.
    Constantinidou A; Alifieris C; Trafalis DT
    Pharmacol Ther; 2019 Feb; 194():84-106. PubMed ID: 30268773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.
    Abdin SM; Zaher DM; Arafa EA; Omar HA
    Cancers (Basel); 2018 Jan; 10(2):. PubMed ID: 29370105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
    Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
    Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
    Rotte A; Jin JY; Lemaire V
    Ann Oncol; 2018 Jan; 29(1):71-83. PubMed ID: 29069302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
    Seetharamu N; Preeshagul IR; Sullivan KM
    Lung Cancer (Auckl); 2017; 8():67-78. PubMed ID: 28761384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Immunotherapy Combinations.
    Bashir B; Wilson MA
    Curr Oncol Rep; 2019 Nov; 21(11):96. PubMed ID: 31696332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.
    Li K; Tian H
    J Drug Target; 2019 Mar; 27(3):244-256. PubMed ID: 29448849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibition in ovarian cancer.
    Hamanishi J; Mandai M; Konishi I
    Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.